Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Management of mCRPC During COVID-19

March 18th 2020

Counseling Patients With mCRPC

March 18th 2020

CARD Trial In Metastatic CRPC

March 18th 2020

Cabazitaxel for the Treatment of mCRPC

March 18th 2020

Using Taxanes Frontline in Metastatic Prostate Cancer

March 18th 2020

Checkpoint Inhibitor Therapy in Prostate Cancer

March 18th 2020

PARP Inhibitors in Castrate-Resistant Prostate Cancer

March 18th 2020

Impact of the CARD Trial for Treating Metastatic CRPC

March 18th 2020

Repeat Molecular Testing in Advanced Prostate Cancer

March 18th 2020

Sequencing Therapy in Castrate-Resistant Prostate Cancer

March 18th 2020

The Use of Taxanes Earlier in Prostate Cancer

March 18th 2020

Dr. Agarwal on Impact of the TITAN Trial With Apalutamide Plus ADT in mCSPC

March 18th 2020

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Dr. Fendler on the Impact of 68Ga-PSMA-11 PET Imaging on Prostate Cancer Management

March 18th 2020

Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.

Experts Weigh In on Top Abstracts From Genitourinary Cancers Symposium

March 18th 2020

How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium.

Dr. Graff on the Safety of Checkpoint Inhibition in mCRPC

March 18th 2020

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Dr. Grivas on PARP inhibition in Germline and DNA Damage Repair-Mutated mCRPC

March 18th 2020

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Dr. Cone on Cardiac Toxicity With GnRH Agonists in Prostate Cancer

March 18th 2020

Eugene B. Cone, MD, urologist, Massachusetts General Hospital, discusses the cardiac toxicity associated with gonadotropin-releasing hormone (GnRH) agonists in prostate cancer.

Pembrolizumab Plus Enzalutamide Shows Moderate Activity in mCRPC

March 17th 2020

Julie N. Graff, MD, discusses the results of the KEYNOTE-199 trial, the importance of combination strategies in metastatic castration-resistant prostate cancer, and the next phase of research for the combination.

Dr. Agarwal on the COSMIC-021 Trial Design in Castration-Resistant Prostate Cancer

March 17th 2020

Neeraj Agarwal, MD, discusses the design of cohort 6 in the phase Ib COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate Cancer

March 17th 2020

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.